Although studies of psychedelic-assisted psychotherapy are accumulating, there is no consensus regarding best practice of the psychotherapeutic component. In this systematic review, we summarised the quality of reporting on psychological interventions in research about psychedelic treatments. The design followed PRISMA guidelines and was preregistered in PROSPERO (CRD42022319221). We searched MEDLINE, PsycINFO, and Embase for original studies on psychedelic-assisted psychotherapy and included 45 studies assessing psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (known as LSD), or ayahuasca, for the treatment of mental disorders. Psychological interventions were done heterogeneously across studies, and completeness of information reported about these interventions was mostly low, according to an adaptation of the Template for Intervention Description and Replication checklist. In studies including MDMA, psychotherapy was more homogeneous and more procedural details were provided. Improved reporting on psychological interventions of psychedelic treatments will support replicability, generalisability, and accurate interpretation of research, while enhancing feasibility and safety of future clinical research and real-world implementation of treatments.

中文翻译：

---

迷幻药治疗中心理干预的报告质量：系统评价


尽管关于迷幻药辅助心理治疗的研究正在积累，但关于心理治疗成分的最佳实践尚未达成共识。在本系统综述中，我们总结了迷幻药治疗研究中心理干预报告的质量。该设计遵循 PRISMA 指南，并在 PROSPERO （CRD42022319221） 中进行了预注册。我们检索了MEDLINE、PsycINFO和Embase，以寻找关于迷幻药辅助心理治疗的原始研究，并纳入了45项评估裸盖菇素、3,4-亚甲二氧基甲基苯丙胺（MDMA）、麦角酸二乙胺（称为LSD）或死藤水治疗精神障碍的研究。根据干预描述和复制清单模板的改编，心理干预在研究中是异质进行的，并且有关这些干预报告的信息完整性大多较低。在包括 MDMA 在内的研究中，心理治疗更加同质，并且提供了更多的程序细节。改进对迷幻药治疗的心理干预报告将支持研究的可重复性、普遍性和准确解释，同时提高未来临床研究和治疗实际实施的可行性和安全性。